Fig 1.
PartSA, partitioned survival approach.
Table 1.
AIC and BIC of survival curve in two groups.
Table 2.
Parameter distribution of survival curve in two groups.
Fig 2.
Optimal curve fitting extrapolation of two treatment schemes.
A. Simulated PFS curve; B. Simulated OS curve.
Table 3.
Model Parameters.
Table 4.
Baseline results.
Table 5.
Results of scenario analyses under different simulation time horizons.
Table 6.
Effects of different simulation distribution approaches on the ICER.
Table 7.
ICER values at different discount rates for drug prices.
Fig 3.
Tornado diagram for one-way sensitivity analysis.
Fig 4.
Acceptability curves.
Fig 5.
Results of Monte Carlo probabilistic sensitivity analysis showing incremental cost-effective of finotonlimab plus bevacizumab biosimilar versus sorafenib.